Immunocine Cancer Center Appoints Vita S. Salsman as Executive Director

Salsman brings more than 20 years of experience in cancer immunotherapy, cell therapy manufacturing, and translational medicine. Throughout her career, she has helped move innovative therapies from early research into clinical development.

Her expertise includes cell therapy manufacturing, clinical operations, quality systems, regulatory strategy and translational medicine, making her well suited to lead the organization's future initiatives.

Read More:Accruent and Carter Synergy Partner to Reduce Downtime

Vita S. Salsman began her career in cellular immunotherapy at Baylor College of Medicine's Center for Cell and Gene Therapy and Texas Children's Hospital. She advanced from research scientist to Director, leading research laboratories, GMP manufacturing and clinical operations. During her time there, she helped drive pioneering cell therapy programs and coauthored several peer reviewed studies on immune-based cancer treatments.

Years before joining Immunocine, both Salsman and the company's founder and CEO, Matt Halpert, PhD, contributed to the same published research paper on immune-based cancer therapies at Baylor. They have now reunited at Immunocine to help advance the company's personalized cancer immunotherapy programs.

After leaving Baylor, Vita S. Salsman held senior leadership roles at several biotechnology companies. At K2 BioLabs she served as Director of Quality Assurance, and Laboratory Operations, where she developed quality systems for companies working on advanced cell therapies.

Most recently, she was Head of Manufacturing at cTRL Therapeutics, leading the production of next-generation cell therapies for clinical use. She also oversaw manufacturing strategy, regulatory submissions, and cross-functional product development programs.

“Vita brings exceptional scientific expertise, operational leadership, and a deep understanding of how to translate innovative research into meaningful patient care,” said Matt Halpert, Ph.D., Founder and Chief Executive Officer of Immunocine Cancer Center. “Her experience advancing cellular therapies from the laboratory to the clinic will be instrumental as we continue to expand our platform and bring personalized immunotherapy to more patients.”

“I feel immensely blessed to have found the beautiful intersection of my two greatest passions—science and medicine—and that both serve what matters most to me: making a meaningful difference in the lives of cancer patients and their families,” said Salsman. “Joining Immunocine feels like the natural culmination of my life’s work to this point.”

About Immunocine Cancer Center

Founded in 2021 by Matthew Halpert, Immunocine Cancer Center develops personalized cancer treatments using its proprietary dendritic cell immunotherapy platform. The technology is designed to help a patient's immune system recognize and fight cancer, with the goal of improving treatment outcomes for patients around the world.

Read More:Acorn Health Appoints Laura Hinson as Chief Financial Officer